Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Fondazione Telethon Ets currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, indicating a high degree of examiner variety relative to the total volume of pending work. Despite this spread of personnel, all prosecution activity is concentrated within 1 distinct art unit. This concentration suggests that while different individuals are reviewing the applications, the technical subject matter remains within a singular specialized group at the patent office.
The busiest examiner for this portfolio is KOSACK, JOSEPH R, who is responsible for 1 pending office action. This single action represents the maximum workload assigned to any individual examiner currently handling the company's patent applications. Because there are 3 distinct examiners for 3 total actions, the workload is perfectly balanced across the involved staff. The focus on 1 distinct art unit for all 3 pending office actions implies a narrow technical specialization for the current pending matters in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
| KOSACK, JOSEPH R | 1 | 74.8% | -6.2% |
| MONTANARI, DAVID A | 1 | 64.7% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547461 | USE OF MICRORNAS IN THE TREATMENT OF FIBROSIS | MONTANARI, DAVID A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18858168 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR USE IN THE TREATMENT OF COGNITIVE DECLINE | REILLY, SOPHIA JANE | — |
| 18547461 | USE OF MICRORNAS IN THE TREATMENT OF FIBROSIS | MONTANARI, DAVID A | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858168 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR USE IN THE TREATMENT OF COGNITIVE DECLINE | REILLY, SOPHIA JANE | — | §103§112DP | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18858015 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR USE IN THE TREATMENT OF COGNITIVE DECLINE | KOSACK, JOSEPH R | — | §102 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18547461 | USE OF MICRORNAS IN THE TREATMENT OF FIBROSIS | MONTANARI, DAVID A | 1632 | §102§103§112 | Non-Final OA | — | Pending | Aug 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial